Hyderabad-based CSIR-IICT and Lee Pharma have signed an agreement for synthesis of DRDO-developed anti-Covid drug 2-DG.
2-DG, developed by DRDO and Dr Reddy’s Laboratories, has received approval for use in Covid-19 treatment. (Photo: India Today/Manjeet Negi)
Hyderabad-based Indian Institute of Chemical Technology, a constituent laboratory of Council of Scientific and Industrial Research (CSIR-IICT,) and pharmaceutical company Lee Pharma have entered into a non-exclusive licensing agreement for the synthesis of 2-Deoxy-D-Glucose (2-DG).
Recently, 2-DG, developed by the Defence Research and Development Organisation (DRDO) and Dr Reddy’s Laboratories, has received approval for emergency use in moderate to severe cases of Covid-19.
The drug has been found to enable faster recovery of hospitalised Covid-19 patients and reduces their supplemental oxygen dependence. Dr. Reddy’s Laboratories has launched the drug in the form of sachets.
An anti-COVID-19 therapeutic application of the drug 2-deoxy-D-glucose (2-DG) has been developed by INMAS, a lab of DRDO, in collaboration with Dr Reddy’s Laboratories, Hyderabad. The drug will help in faster recovery of Covid-19 patients. https://t.co/HBKdAnZCCP pic.twitter.com/8D6TDdcoI7
— DRDO (@DRDO_India) May 8, 2021
Director of CSIR-IICT Dr. Srivari Chandrashekar said, “There is role of CSIR in development of 2-DG, as CSIR-CCMB tested the drug on SARS-CoV-2 viral cultures. CSIR has been engaged in development of drugs for treatment of Covid-19 and has undertaken many clinical trials for repurposed drugs.”
Dr. Srivari Chandrashekar added that, “Additionally, this agreement with Lee Pharma Ltd. is towards increasing affordable therapeutic options for treatment of Covid-19” said Dr. Srivari Chandrashekar, Director CSIR-IICT.”
Lee Pharma will file the application for getting the approval from Drugs Controller General of India (DCGI).
The company will manufacture and commercialise the 2-DG sachets from their formulation facility located at SEZ in Andhra Pradesh’s Visakhapatnam, which has the accreditations by global regulatory agencies.
Click here for IndiaToday.in’s complete coverage of the coronavirus pandemic.